4 assets in Triple-Positive Breast Carcinoma

Therapeutic assets addressing Triple-Positive Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pertuzumab Triple-Positive Breast Carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	BB (64)
Trastuzumab Triple-Positive Breast Carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	B (60)
Fovinaciclib Triple-Positive Breast Carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (53)
Elacestrant Triple-Positive Breast Carcinoma	NYU Langone Health	P1/2	CCC (48)